GC Cell, a prominent South Korean cell and gene therapy company, successfully hosted its inaugural thought leadership symposium in Jakarta, Indonesia. Organized in partnership with PT Bifarma Adiluhung (Bifarma), a leading player in Indonesia’s stem cell therapy industry, the event highlighted GC Cell’s advanced cancer immunotherapy, Immuncell-LC.
The symposium centered on key insights into Immuncell-LC’s mechanisms of action, real-world treatment applications, and clinical case studies. Indonesian oncologists participated in in-depth discussions with distinguished Korean medical experts who have applied the therapy in clinical trials, exploring its clinical potential and effectiveness.
As the first international event dedicated to Korea-developed cell therapy, the symposium represents a significant milestone for the industry. By enhancing trust and market presence in Indonesia, GC Cell is advancing the global commercialization of Immuncell-LC, positioning it as a leading treatment option for cancer patients worldwide.
Following the licensing agreement signed with Bifarma in September 2024, GC Cell has been facilitating technology transfer to support local production and quality control. The six-month program at GC Cell’s headquarters is progressing as planned, positioning Bifarma to introduce Immuncell-LC to the Indonesian market by 2025.
GC Cell’s partnership with Bifarma aligns with its broader expansion strategy into international markets. It provides advanced cell therapies to enhance patient outcomes globally while strengthening its position in the rapidly evolving biotechnology sector.
(Source: BioSpace)
